BDr. Bruce Jeffrey Trock is the Frank Hinman Jr. endowed Professor of Urology, and is Professor of Epidemiology and Oncology at the Johns Hopkins School of Medicine. He serves as the Director of the Division of Epidemiology in the Brady Urological Institute at Johns Hopkins. His research focuses on prostate cancer. Prior to joining Johns Hopkins, Dr. Trock was a tenured associate professor at Georgetown University’s Lombardi Cancer Center, where he was also Director of the Cancer Biomarker Resource, with prior positions at the Fox Chase Cancer Center, and the University of Pennsylvania.
In addition to his faculty appointments at Johns Hopkins, Dr. Trock is the Director of the Biostatistics Core for the Johns Hopkins Specialized Program of Research Excellence (SPORE) in Prostate Cancer. He also was the founding Director, and is now Co-Director of the Prostate Cancer Biorepository Network, a collaboration between the Johns Hopkins University School of Medicine, the New York University School of Medicine, University of Washington, the Institute of Cancer Research (London), Washington University, and the United States Department of Defense that provides high quality, well-annotated prostate cancer tissues and biospecimens to prostate cancer researchers worldwide.
Dr. Trock has authored or co-authored more than 270 published articles and has been principal or co-principal investigator on numerous research grants.
Hopkins University School of Hygiene
Doctor of Philosophy, Epidemiology
Chairman: Leon Gordis, M.D.
of Michigan School of Public Health
Ann Arbor, MI
Master of Public Health, Epidemiology
of Michigan -Ann Arbor, MI
Bachelor of Science, Mathematics
Lawrence CE, Taylor PR, Trock BJ, Reilly AA: Trihalomethanes in drinking water and human colorectal cancer. J Nat Cancer Inst 72(3): 563-568, 1984.
Weed DL, Trock BJ: Criticism and the growth of epidemiologic knowledge. (Letter) AmerJ of Epidemiol 123(6): 1119-1120, 1986.
Weed DL, Trock BJ: Interactions and public health decisions. J Clin Epi 41: 207-209, 1988.
Clark WH, Elder DE, Guerry D, Braitman LE, Trock BJ, et al. A model predicting survival in Stage I melanoma based upon tumor progression and multivariable logistic regression. JNCI 81: 1893-1904, 1989.
King E, Rimer BK, Trock B, Balshem A, Engstrom P: How valid are mammography self-reports? Amer J of Public Health 80(11): 1386-1388, 1990.
NCI Breast Cancer Screening Consortium. Screening mammography: A missed clinical opportunity. JAMA 264: 54-58, 1990.
Lerman C, Rimer B, Trock B, et al. Factors associated with repeat adherence to breast cancer screening. Prev Med 19: 279-290, 1990.
Myers RE, Trock BJ, Lerman C, et al.Adherence to colorectal screening in an HMO population. Prev Med 19: 502-514, 1990.
Rimer BK, Trock BJ, et al. Breast screening practices among primary physicians: Reality and potential. J Amer Board of Family Practice 3: 26-34, 1990.
Rimer BK, Trock BJ: Letter to the Editor. J Amer Board of Family Practice 3: 140-1, 1990.
Rosenthal SA, Trock BJ, Coia LR: Randomized trials of adjuvant radiation therapy for rectal carcinoma: A Review. Dis of Colon and Rectum 33: 335-343, 1990.
Corn BW, Trock BJ, Goodman RL: Radiation-related ischemic heart disease. J Clin Oncol 8: 1-10, 1990.
Hernandez DJ, Epstein JI, Trock BJ, Tsuzuki T, Carter HB, Walsh PC. Radical retropubic prostatectomy: how often do experienced surgeons have positive surgical margins when there is extraprostatic extension in the region of the neurovascular bundle? J Urol 2005; 173:446-9.
Stearns V, Coop A, Singh B, Gallagher A, Yamauchi Y, Lieberman R, Pennanen M, Trock B, Hayes DF, Ellis MJ.A pilot surrogate endpoint biomarker trial of perillyl alcohol (POH) in breast neoplasia. Clin Cancer Res 2004; 10:7583-7591.
Stearns V, Gallagher A, Kleer CG, Singh B, Freedman M, Haddad BR, Isaacs C, Warren R, Brown M, Cullen J, Trock B, Hayes DF. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity. Clin Cancer Res 2004; 10:8332-8340.
Tsuzuki T, Hernandez DJ, Aydin H, Trock B, Walsh PC, Epstein JI. Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination. J Urol 2005; 173:450-3.
Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA, Lee H, Temple K, Graves R, Pollard J, Chopra N, Russell RG, Sasisekharan R, Trock BJ, Lippman M, Calvert VS, Petricoin EF 3rd, Liotta L, Dadachova E, Pestell RG, Lisanti MP, Bonaldo P, Scherer PE. < Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest 2005; 115:1163-76.
Petricoin EF 3rd, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, Belluco C, Trock BJ, Lippman M, Fishman DA, Sgroi DC, Munson PJ, Esserman LJ, Liotta LA. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol. 2005; 23:3614-21.
Ellison LM, Trock BJ, Poe NR, Partin AW. The effect of hospital volume on cancer control after radical prostatectomy. J Urol 2005;173:2094-8.
Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005; 11:4037-43.
Gonzalgo ML, Pavlovich CP, Trock BJ, Link RE, Sullivan W, Su LM. Classification and trends of perioperative morbidities following laparoscopic radical prostatectomy. J Urol 2005; 174:135-9.
Trock B. Invited editorial comment re: Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study. J Urol 2005; 174:499.
Freedland SJ, Aronson WJ, Trock B, Cohen P, Kane CJ, Amling CL, Presti JC Jr, Terris MK. Racial differences in prognostic value of adult height for biochemical progression following radical prostatectomy. Clin Cancer Res 2005; 11:7735-42.
Clarke R, Leonessa F, Trock B. Multidrug resistance/p-glycoprotein and breast cancer: review and meta-analysis. Seminars in Oncol 2005; 32(6 Suppl 7):S9-15.
Rais-Bahrami S, Lima GC, Varkarakis IM, Romero FR, Trock B, Jarrett TW, Kavoussi LR. Intraoperative conversion of laparoscopic partial nephrectomy. J Endourol 2006; 20:205-8.
Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 2006; 98:355-7.
Gonzalgo ML, Bastian PJ, Mangold LA, Trock BJ, Epstein JI, Walsh PC, Partin AW. Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. Urology 2006; 67:115-9.
Trock B, Clarke R, Hilakivi-Clarke L. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst 2006; 98:459-471.
97. Markushin Y, Gaikwad N, Zhang H, Kapke P, Rogan EG, Cavalieri EL, Trock BJ, Pavlovic C, Jankowiak R. Potential biomarker for early risk assessment of prostate cancer. The Prostate 2006; 66:1565-1571.
Prowell TM, Stearns V, Trock B. Lipophilic statins merit additional study for breast cancer chemoprevention. J Clin Oncol 2006; 24:2128-9.
Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ, Metter EJ. Detection of life-threatening prostate cancer with PSA velocity during a window of curability. J Natl Cancer Inst 2006; 98:1521-1527.
Parsons JK, Partin AW, Trock B, Bruzek DJ, Cheli C, Sokoll LJ. Complexed prostate- specific antigen for the diagnosis of biochemical recurrence after radical prostatectomy. BJU Int 2007; 99:758-61.
Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW. Updated nomogram to predict pathologic stage of prostate cancer given PSA, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000-2005. Urology 2007; 69:1095-1101.
Bastian PJ, Palapattu GS, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, Trock BJ, et al. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin Cancer Res 2007; 13:5361-5367.
Magheli A, Rais-Bahrami S, Peck HJ, Walsh PC, Epstein JI, Trock BJ, et al. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy. J Urol 2007; 178:1311-1315
Romero FR, Schaeffer EM, Muntener M, Trock BJ, Kavoussi LR, Jarrett TW. Oncologic outcomes of extravesical stapling of distal ureter in laparoscopic nephroureterectomy. J Endourol 2007; 21:1025-1028.
Zheng SL, Sun J, Cheng Y, Li G, Hsu FC, Zhu Y, Chang BL, Liu W, Kim JW, Turner AR, Gielzak M, Yan G, Isaacs SD, Wiley KE, Sauvageot J, Chen HS, Gurganus R, Mangold LA, Trock BJ, Gronberg H, et al. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst 2007; 1525-1533.
Magheli A, Rais-Bahrami S, Humphreys EB, Peck HJ, Trock BJ, Gonzalgo ML. Impact of patient age on biochemical recurrence rates following radical prostatectomy. J Urol 2007; 178:1933-1937.
Wagner AA, Link RE, Trock BJ, Sullivan W, Pavlovich CP. Comparison of open and laparoscopic radical prostatectomy outcomes from a surgeon’s early experience. Urology 2007; 70:667-671.
Nielsen ME, Bastian PJ, Palapattu GS, Trock BJ, Schoenberg MP, Chan T, Rogers CG. Recurrence-free survival after radical cystectomy of patients downstaged by transurethral resection. Urology 2007; 70:1091-1095.
Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F, Robbins C, Isaacs SD, Cheng Y, Li G, Sun J, Chang BL, Marovich L, Wiley KE, Balter K, Stattin P, Adami HO, Gielzak M, Yan G, Sauvageot J, Liu W, Kim JW, Bleecker ER, Meyers DA, Trock BJ, Partin AW, Walsh PC, Isaacs WB, Gronberg H, Xu J, Carpten JD. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007; 99:1836-1844.
Semins MJ, Trock BJ, Matlaga BR. The effect of shock wave rate on the outcome of shock-wave lithotripsy: a meta-analysis. J Urol 2008; 179:194-197; discussion 197.
Makarov DV, Humphreys EB, Mangold LA, Carducci MA, Partin AW, Eisenberger MA, Walsh PC, Trock BJ. The natural history of men managed with deferred androgen deprivation therapy who developed metastatic prostate cancer following radical prostatectomy. J Urol 2008; 179:156-161; discussion 161-162.
Hoque MH, Begum S, Brait M, Jeronimo C, Zahurak M, Ostrow K, Rosenbaum E, Trock BJ, Westra WH, Schoenberg M, Goodman SN, Sidransky D. TIMP3 promoter methylation is an independent prognostic factor for bladder cancer. J Urol 2008; 179(2):743-7.
Bastian PJ, Palapattu GS, Yegnasubramanian S, Rogers CG, Lin X, Mangold LA, Trock BJ, Eisenberger MA, Partin AW, Nelson WG. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol 2008; 179(2):529-34; discussion 534-5.
Pavlovich CP, Trock BJ, Sulman A, Wagner AA, Mettee LZ, Su LM. 3-year actuarial biochemical recurrence-free survival following laparoscopic radical prostatectomy: experience from a tertiary referral center in the United States. J Urol 2008; 179(3):917-21; discussion 921-2.
Landefeld CS, Bowers BJ, Feld AD, Hartmann KE, Hoffman E, Ingber MJ, King JT Jr, McDougal WS, Nelson H, Orav EJ, Pignone M, Richardson LH, Rohrbaugh RM, Siebens HC, Trock BJ. National Institutes of Health State-of-the-Science Statement: Prevention of fecal and urinary incontinence in adults. Ann Intern Med 2008; 148(6):449-58.
Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, Gonzalgo ML. Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy. J Urol 2008; 179(5):1780-4; discussion 1784.
Makarov DV, Trock BJ, Allaf ME, Matlaga BR. The effect of ureteral stent placement on post-ureteroscopy complications: a meta-analysis. Urology 2008; 71(5):796-800.
Trock BJ. Seminar section introduction: A clinician’s guide to statistical methods in urologic oncology. Urol Oncol 2008; 26(3):299.
Deo DD, Rao AP, Bose SS, Ouhtit A, Baliga SB, Rao SA, Trock BJ, Thouta R, et al. Differential effects of leptin on the invasive potential of androgen-dependent and independent prostate carcinoma cells. J Biomed Biotechnol 2008; 2008(163902): 1-8.
Hernandez DJ, Nielsen ME, Han M, Trock BJ, Partin AW, Walsh PC, Epstein JI. Natural history of pathologically organ-confined (pT2), gleason score 6 or less, prostate cancer after radical prostatectomy. Urology 2008; 72(1):172-6.
Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC. Prostate cancer-specific survival following salvage radiotherapy vs. observation in men with biochemical recurrence after radical prostatectomy: JAMA 2008; 299(23):2760-9.
Sun J, Chang BL, Isaacs SD, Wiley KE, Wiklund F, Stattin P, Duggan D, Carpten JD, Trock BJ, Partin AW, Walsh PC, Grönberg H, Xu J, Isaacs WB, Zheng SL. Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate 2008; 68(12):1257-62.
Sun J, Zheng SL, Wiklund F, Isaacs SD, Purcell LD, Gao Z, Hsu FC, Kim ST, Liu W, Zhu Y, Stattin P, Adami HO, Wiley KE, Dimitrov L, Sun J, Li T, Turner AR, Adams TS, Adolfsson J, Johansson JE, Lowey J, Trock BJ, Partin AW, et al. Evidence of two independent prostate cancer risk-associated loci in HNF1B gene at 17q12. Nat Genet 2008; 40(10):1153-5.
Xu J, Isaacs SD, Sun J, Li G, Wiley KE, Zhu , Hsu FC, Wiklund F, Turner AR, Adams TS, Liu W, Trock BJ, Partin AW, Chang B, Walsh PC, Grönberg H, Isaacs W, Zheng S. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res 2008; 14(18):5819-24.
Rais-Bahrami S, Romero FR, Lima GC, Kohanim S, Permpongkosol S, Trock BJ, Jarrett TW, Kavoussi LR. Elective laparoscopic partial nephrectomy in patients with tumors >4 cm. Urology 2008; 72(3):580-3.
Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, Gonzalgo ML. Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching. Urology 2008; 72(6):1246-51.
Burnett AL, Strong TD, Trock BJ, Jin L, Bivalacqua TJ, Musicki B. Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in Type 2 diabetic men with erectile dysfunction. J Urol 2009; 181(1):245-51.
Semins MJ, Trock BJ, Matlaga BR. The safety of ureteroscopy during pregnancy: A Systematic review and meta-analysis. J Urol 2009; 181:139-43.
Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, Metter EJ. Prostate specific antigen testing among the elderly—when to stop? J Urol 2009; 181: 1606-14.
Yang L, Gaikwad NW, Meza J, Cavalieri EL, Trock BJ, Rogan EG. Novel biomarkers for risk of prostate cancer: Results from a case-control study. Prostate 2009; 69:41-8.
Richstone L, Seideman CA, Reggio E, Bluebond-Langner R, Pinto PA, Trock B, Kavoussi LR. Pathological findings in patients with ureteropelvic junction obstruction and crossing vessels. Urology 2009; 73:716-9.
Kader AK, Sun J, Isaacs SD, Wiley KE, Yan G, Kim ST, Fedor H, Demarzo AM, Epstein JI, Walsh PC, Partin AW, Trock B, Zheng SL, Xu J, Issacs W. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate 2009; 69:1195-1205.
Trock BJ, Guo CC, Gonzalgo ML, Maheli A, Loeb S, Epstein JI. Tertiary Gleason patterns and biochemical recurrence after radical prostatectomy: proposal for a modified Gleason scoring system. J Urol 2009; 182:1364-70.
Novak TE, Lakshmanan Y, Trock BJ, Gearhart JP, Matlaga BR. Sex prevalence of pediatric kidney stone disease in the united states: an epidemiologic investigation. Urology 2009; 74:104-7.
Bañez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Prestijr JC, Kane CJ, Amling CL, Moul JW, Freedland SJ. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol 2009; 182:491-6.
Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology 2010; 76:710-4.
Tseng KS, Landis P, Epstein JI, Trock BJ, Carter HB. Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol 2010; 183:1779-85.
Trock BJ, Walsh PC. Re: Radiation therapy after radical prostatectomy: impact on metastasis and survival S. A. Boorjian, R. J. Karnes, P. L. Crispen, L. J. Rangel, E. J. Bergstralh and M. L. Blute J Urol 2009; 182: 2708-2715. J Urol 2010; 183:2466-7;
Sidana A, Aggarwal P, Feng Z, Georgiades CS, Trock BJ, Rodriguez R. Complications of renal cryoablation: a single center experience. J Urol 2010; 194:42-7.
Matlaga BR, Schaeffer AJ, Novak TE, Trock BJ. Epidemiologic insights into pediatric kidney stone disease. Urol Res 2010; 38:453-7.
Trock BJ, Walsh PC. Re: Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death (letter). Cancer 2011; 117:656
Han M, Kim C, Mozer P, Schafer F, Badaan S, Vigaru B, Tseng K, Petrisor D, Trock B, Stoianovici D. Tandem-robot assisted laparoscopic radical prostatectomy to improve the neurovascular bundle visualization: a feasibility study. Urology 2011; 77:502-6.
Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ. Predicting 15-year prostate cancer-specific mortality after radical prostatectomy. J Urol 2011; 185:869-75.
Schaeffer AJ, Feng Z, Trock BJ, Mathews RI, Neu AM, Gearhart JP, Matlaga BR. Medical comorbidities associated with pediatric kidney stone disease. Urology 2011; 77:195-9.
Lin BM, Hyndman ME, Steele KE, Feng Z, Trock BJ, Schweitzer MA, Pavlovich CP. Incidence and risk factors for inguinal and incisional hernia after laparoscopic radical prostatectomy. Urology 2011; 77:957-62.
Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB. Active surveillance for very low-risk prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29:2185-90.
Eifler JB, Levinson AW, Hyndman ME, Trock BJ, Pavlovich CP. Pelvic lymph node dissection is associated with symptomatic venous thromboembolism risk during laparoscopic radical prostatectomy. J Urol 2011; 185:1661-5.
Loeb S, Feng Z, Ross A, Trock BJ, Humphreys EB, Walsh PC. Can we stop prostate- specific antigen testing 10 years after radical prostatectomy? J Urol 2011; 186:500-5.
Karram S, Trock BJ, Netto GJ, Epstein JI. Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. Am J Surg Pathol 2011; 35:1351-5.
Shiraishi T, Terada N, Zeng Y, Suyama T, Luo J, Trock B, Kulkarni P, Getzenberg R. Cancer/testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med 2011; 9:153.
Baradan N, Cervellione RM, Orosco R, Trock BJ, Costello J, Mathews R, Gearhart JP. The effect of a failed initial closure on bladder growth in children with bladder exstrophy. J Urol 2011; 186:1450-4.
Trock BJ. Application of metabolomics to prostate cancer. Urol Oncol 2011; 29:572-81.
Trock BJ, Brotzman MJ, Mangold LA, Bigley JW, Epstein JI, McLeod D, Klein EA, Jones JS, Wang S, McAskill T, Mehrotra J, Raghavan B, Partin AW. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in high-risk men with negative initial prostate biopsies. BJUI 2012; 110:56-62.
Loeb S, Trock BJ. Re: Randomised prostate cancer screening trial: 20 year follow-up. Sandblom G, Varenhors E, Rosell J, Lofman O, Carlsson P. BMJ 2011;342:d1539. Eur Urol 2011; 60:1306-7.
Sidana A, Hernandez DJ, Feng Z, Partin AW, Trock BJ, Saha S, Epstein JI. Treatment decision-making for localized prostate cancer: What younger men choose and why. Prostate 2012; 72:58-64.
Antonarakis E, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA. The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: long-term follow-up. BJU Intl 2012; 109:32-9.
Trock BJ. Re: Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease: ND Arvold, MH Chen, JW Moul, BJ Moran, DE Dosoretz, LL Banez, MJ Katin, MH Braccioforte, AF D’Amico. J Urol 2011; 186:91-96. J Urol 2012; 187:356; author reply 356-7.
Willis DL, Gonzalgo ML, Brotzman M, Feng Z, Trock B, Su LM. Comparison of outcomes between pure laparoscopic vs. robot assisted laparoscopic radical prostatectomy: a study of comparative effectiveness based upon validated quality of life outcomes. BJU Int 2012; 109:898-905.
Ross AE, Feng Z, Pierorazio PM, Landis P, Walsh PC, Carter HB, Trock BJ, Schaeffer EM. Effect of treatment with 5-alpha reductase inhibitors on progression in monitored men with favourable risk prostate cancer. BJU Int 2012; 110:651-7.
Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 2012; 61:1019-24.
Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol 2012; 188:1131-6.
Han M, Chang D, Kim C, Lee BJ, Zuo Y, Kim HJ, Petrisor D, Trock B, Partin AW, Rodriguez R, Carter HB, Allaf M, Stoianovici D. Geometric evaluation of systematic transrectal ultrasound-guided prostate biopsy. J Urol 2012; 188:2404-9.
Chalfin H, Feng Z, Dinizo M, Trock BJ, Partin AW, Walsh PC, Humphreys E, Han M. Impact of surgical margin status on prostate cancer-specific mortality. BJU Int 2012; 110:1684-9.
Eifler JB, Humphreys EB, Agro M, Partin AW, Trock BJ, Han M. Causes of death after radical prostatectomy at a large tertiary center. J Urol 2012; 188:798-802.
Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM, Steyerberg EW, Jenster G, Kattan MW, Bellardita L, Carroll PR, Denis LJ, Parker C, Roobol MJ, Emberton M, Klotz LH, Rannikko A, Kakehi Y, Lane JA, Schröder FH, Semjonow A, Trock BJ, Valdagni R. Active surveillance for low-risk prostate cancer. Crit Rev Oncol Hematol 2012 Aug 6 [Epub ahead of print].
Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res 2012; 18:5471-8.
Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. J Urol 2012; 188:2219-24.
Anusionwu I, Baradaran N, Trock BJ, Stec AA, Gearhart JP, Wright EJ. Is pelvic osteotomy associated with lower risk of pelvic organ prolapse in postpubertal females with classic bladder exstrophy? J Urol 2012; 188:2343-6.
Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M, Epstein JI, Walsh PC, Trock BJ, Partin AW. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int 2013; 111:22-9.
Semins MJ, Feng Z, Trock B, Bohlman M, Hosek W, Matlaga BR. Evaluation of acute renal colic: a comparison of non-contrast CT versus 3-T non-contrast HASTE MR urography. Urolithiasis 2013; 41:43-6.
González-Roibón N, Han JS, Lee S, Feng Z, Arslankoz S, Smith N, Pierorazio PM, Humphreys E, Deweese TL, Partin AW, Bivalacqua TJ, Han M, Trock B, Netto GJ. Comparison of biochemical recurrence-free survival between periprostatic and pelvic lymph node metastases of prostate cancer. Int J Surg Pathol 2013; 21:352-7.
Pierorazio PM, Hyams ES, Tsai S, Feng Z, Trock BJ, Mullins JK, Johnson PT, Fishman EK, Allaf ME. Multiphasic enhancement patterns of small renal masses (≤4 cm) on preoperative computed tomography: utility for distinguishing subtypes of renal cell carcinoma, angiomyolipoma, and oncocytoma. Urology 2013; 81:1265-71.
Tosoian JJ, JohnBull E, Trock BJ, Landis P, Epstein JI, Partin AW, Walsh PC, Carter HB. Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol 2013; 190:1218-22.
Sundi D, Reese AC, Mettee LZ, Trock BJ, Pavlovich CP. Laparoscopic and robotic radical prostatectomy outcomes in obese and extremely obese men. Urology 2013; 82:600-5.
Pavlovich CP, Levinson AW, Su LM, Mettee LZ, Feng Z, Bivalacqua TJ, Trock BJ. Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy: results of a randomized double-blind trial with placebo. BJU Int 2013; 112:844-51.
Pierorazio PM, Gorin MA, Ross AE, Feng Z, Trock BJ, Schaeffer EM, Han M, Epstein JI, Partin AW, Walsh PC, Bivalacqua TJ. Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience. Prostate 2013; 73:1673-80.
Patel HD, Feng Z, Landis P, Trock BJ, Epstein JI, Carter HB. Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer. J Urol. 2013 Sep 20. [Epub ahead of print]
Kaye DR, Hyndman ME, Segal RL, Mettee LZ, Trock BJ, Feng Z, Su LM, Bivalacqua TJ, Pavlovich CP. Urology 2013; 82:1348-54. Urinary outcomes are significantly affected by nerve sparing quality during radical prostatectomy.
Darshan M, Zheng Q, Fedor HL, Wyhs N, Yegnasubramanian S, Lee P, Melamed J, Netto GJ, Trock BJ, De Marzo AM, Sfanos KS. Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network. Prostate 2014; 74:61-9.
Inoue LY, Trock BJ, Partin AW, Carter HB, Etzioni R. Modeling grade progression in an active surveillance study. Stat Med. 2013 Oct 9 [Epub ahead of print]
Kryvenko ON, Carter HB, Trock BJ, Epstein JI. “Epstein criteria” for determining appropriateness for active surveillance in the modern era. J Urol (in press).
Trock BJ. Circulating biomarkers for discriminating indolent from aggressive disease in prostate cancer active surveillance. Curr Opin Urol 2014; 24:293-302.
Mukherjee A, Castanares M, Hedayati M, Wabler M, Trock B, Kulkarni P, Rodriguez R, Getzenberg RH, DeWeese TL, Ivkov R, Lupold SE. Monitoring nanoparticle-mediated cellular hyperthermia with a high sensitivity biosensor. Nanomedicine 2014; 9:2729-43.
Tan M, Shao C, Bishop JA, Feng Z, Trock BJ, Westra WH, Ha PK. Aquaporin-1 promoter hypermethylation is associated with improved prognosis in salivary gland adenoid cystic carcinoma. Otolaryngol Head Neck Surg 2014 Feb 3 [Epub ahead of print].
Chalfin HJ, Frank SM, Feng Z, Trock BJ, Drake CG, Partin AW, Humphreys E, Ness PM, Jeong BC, Lee SB, Han M. Allogeneic versus autologous blood transfusion and survival after radical prostatectomy. Transfusion 2014 Mar 6 [Epub ahead of print].
Gorin MA, Chalfin HJ, Epstein JI, Feng Z, Partin AW, Trock BJ. Predicting the risk of non- organ-confined prostate cancer when perineural invasion is found on biopsy. Urology 2014; 83:1117-21.
Trock BJ. Adjuvant radiation following radical prostatectomy: what are the known unknowns? Invited Editorial. Eur Urol 2014; 66:251-2.
Jeong BC, Chalfin HJ, Lee SB, Feng Z, Epstein JI, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M. The relationship between the extent of extraprostatic extension and survival following radical prostatectomy. Eur Urol 2014 Jun 23 [Epub ahead of print].
Kates M, Tosoian JJ, Trock BJ, Feng Z, Carter HB, Partin AW. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and PRIAS protocols. BJU Int 2014 Jun [Epub ahead of print].
Chalfin HJ, Lee SB, Jeong BC, Freedland SJ, Feng Z, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M. Obesity and long term survival after radical prostatectomy. J Urol 2014; 192:1100-4.
Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, Rieger-Christ K, Jones JS, Magi-Galluzzi C, Mangold LA, Trock BJ, Lance RS, Bigley JW, Van Criekinge W, Epstein JI. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol 2014; 192:1081-7.
Cohen JE, Landis P, Trock BJ, Patel HD, Ball MW, Auwaerter PG, Schaeffer E, Carter HB. Fluoroquinolone resistance in the rectal carriage of en in an active surveillance cohort: longitudinal analysis. J Urol. 2015; 193:552-6.
Xia J, Trock BJ, Gulati R, Mallinger L, Cooperberg MR, Carroll PR, Carter HB, Etzioni R. Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. Clin Cancer Res. 2014; 20:5302-10.
Dianat SS, Carter HB, Pienta KJ, Schaeffer EM, Landis PK, Epstein JI, Trock BJ, Macura KJ. Magnetic resonance-invisible versus magnetic resonance-visible prostate cancer in active surveillance: a preliminary report on disease outcomes. Urology. 2015; 85:147-53.
Trock BJ. Editorial Comment on: “Bhindi B, Margel D, Hamilton RJ, et al. The impact of the use of aspirin and other nonsteroidal anti-inflammatory drugs on the risk of prostate cancer detection on biopsy. Urology 2014; 84:1073-8.” Urology 2014; 84:1079.
Sundi D, Faisal FA, Trock BJ, Landis PK, Feng Z, Ross AE, Carter HB, Schaeffer EM. Reclassification rates are higher among African American men than Caucasians on active surveillance. Urology 2015; 85:155-60.
Patel HD, Trock BJ, Han M, Carter HB. Practice patterns and individual variability of surgeons performing radical prostatectomies at a high volume academic center. J Urol 2015; 193:812-19.
Takahashi S, Shiraishi T, Miles N, Trock BJ, Kulkarni P, Getzenberg R. Nanowire analysis of cancer/testis antigens (CTAs) as biomarkers of aggressive prostate cancer. Urology 2015; 85:704.e1-7.
Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Partin A, Han M, Freedland SJ. Is clinical stage T2c prostate cancer an intermediate- or high-risk disease? Cancer 2015; 121:1414-21.
Ko JS, Chalfin H, Trock BJ, Feng Z, Humphreys E, Park SW, Carter HB, Frick KD, Han M. Variability in Medicare utilization and payment among urologists. Urology 2015; 85:1045-50.
Pierorazio PM, Johnson MH, Ball MW, Gorin MA, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: The DISSRM Registry. Eur Urol 2015; 68:408-15.
Ball MW, Gorin MA, Bhayani SB, Rogers CG, Stifelman MD, Kaouk JH, Zargar H, Marshall S, Larson JA, Rahbar HM, Trock BJ, Pierorazio PM, Allaf ME. Preoperative predictors of malignancy and unfavorable pathology for clinical T1a tumors treated with partial nephrectomy: A multi-institutional analysis. Urol Oncol 2015; 33:112.e9-112.e14.
Ross AE, Yousefi K, Davicioni E, Ghadessi M, Johnson MH, Sundi D, Tosoian JJ, Han M, Humphreys EB, Partin AW, Walsh PC, Trock BJ, Schaeffer EM. Utility of risk models in decision making after radical prostatectomy: lessons from a natural history cohort of intermediate- and high-risk men. Eur Urol 2015 Apr 25 [Epub ahead of print].
Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Eur Urol 2015 Oct;68(4):555-67.
Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L, Fedor HL, Glavaris S, Choeurng V, Buerki C, Erho N, Lam LL, Humphreys EB, Faraj S, Bezerra SM, Han M, Partin AW, Trock BJ, Schaeffer EM. Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men. Eur Urol 2016; 69:157-65.
Malmström PU, Trock BJ. Re: Richard J. Sylvester, Willem Oosterlinck, Sten Holmang, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pta-pt1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol In press. Eur Urol 2016; 69:e10-1.
Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 2015; 33:3379-85.
Reese AC, Feng Z, Landis P, Trock BJ, Epstein JI, Carter HB. Predictors of adverse pathology in men undergoing radical prostatectomy following initial active surveillance. Urology 2015; 86:991-7.
Tosoian JJ, Sundi D, Trock BJ, Landis P, Epstein JI, Schaeffer EM, Carter HB, Mamawala M. Pathologic outcomes in favorable-risk prostate cancer: comparative analysis of men electing active surveillance and immediate surgery. Eur Urol 2015 Oct 5 [EPub ahead of Print].
Faraj SF, Bezerra SM, Yousefi K, Fedor H, Glavaris S, Han M, Partin AW, Humphreys E, Tosoian J, Johnson MH, Davicioni E, Trock BJ, Schaeffer EM, Ross AE, Netto GJ. Clinical validation of the 2005 ISUP Gleason grading system in a cohort of intermediate and high risk men undergoing radical prostatectomy. PLoS One 2016;11:e0146189
|7/1/01-6/30/02||Principal Investigator. Impact of Environmental Cadmium Exposure on Prostate Cancer Risk in the Baltimore Metropolitan Area. Maryland Cigarette Restitution Fund|
|10/1/99-9/30/04||Principal Investigator. Detecting Breast Cancer Protein Signatures in Body Fluids. National Cancer Institute|
|10/1/99-9/30/02||Principal Investigator. Molecular Epidemiology of Prostate Cancer. Department of Defense|
|7/1/98-6/30/01||Principal Investigator. Angiogenic growth factors in nipple aspirate fluid. Department of Defense|
|1996-1999||Principal Investigator. Role of Cadmium in the Development of Breast Cancer. American Cancer Society|
|1993-1996||Principal Investigator. Molecular Epidemiology of Head and Neck Cancer. American Cancer Society|
|1995- 2000||Principal Investigator. Breast Cancer Serum Bank Core Facility - SPORE in Breast Cancer. National Cancer Institute|
|1996-1997||Principal Investigator. Early Detection Based on p53 in Nipple Aspirate Fluid. Cancer Research Foundation of American|
|1996-2000||Co-Principal Investigator. A Coordinated Approach to Breast Cancer Diagnosis. Department of Defense|